Oxford Biomedica plc
OXB.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | -0.00 | 0.04 | -0.14 |
| FCF Yield | -13.38% | -18.05% | -6.89% | 1.56% |
| EV / EBITDA | -33.67 | -1.48 | -36.14 | 27.91 |
| Quality | ||||
| ROIC | -22.78% | -83.55% | -7.29% | 9.66% |
| Gross Margin | 41.17% | 44.37% | 49.42% | 57.87% |
| Cash Conversion Ratio | 1.07 | 0.18 | 0.27 | 1.28 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.74% | -14.41% | 16.86% | 30.63% |
| Free Cash Flow Growth | -51.57% | -32.65% | -280.76% | 256.16% |
| Safety | ||||
| Net Debt / EBITDA | -3.36 | -0.05 | 2.49 | -3.00 |
| Interest Coverage | -4.00 | -16.45 | -3.45 | 23.39 |
| Efficiency | ||||
| Inventory Turnover | 5.58 | 3.87 | 5.61 | 6.32 |
| Cash Conversion Cycle | 138.42 | 104.36 | 145.12 | 133.45 |